- Reference code :
- wf403
- Published date :
-
31 October 2001
- Expired date :
-
18 March 2029
AstraZeneca today announced that the Oslo Byrett (Oslo City Court) in Norway found that a generic omeprazole product marketed by Scandinavian Pharmaceuticals-Generics AB (Scand Pharm) infringes AstraZeneca’s formulation patent for omeprazole, the substance used in Losec. At the same time, the Court declared AstraZeneca’s omeprazole formulation patent valid.
The written judgement followed a hearing, which ended on October 9.
Previously AstraZeneca had been granted a preliminary injunction in May last year (2000) against Scand Pharm to prevent the sale of its generic version of omeprazole. Scand Pharm had launched its version of omeprazole in Norway in December 1999.
Sales of Losec MUPs® in Norway account for less than 0.5 per cent of AstraZeneca’s worldwide Losec sales. Losec is a treatment for stomach acid disorders.
Dr Martin Nicklasson, Executive Vice President, GI Franchise of AstraZeneca said "We are delighted by today's judgement in our favour, as it underscores the strength of our intellectual property and the validity of our formulation patent for Losec.”
Further enquires to:
Media RelationsEmily Denney +44 (0)20 7304 5034 |
Investor RelationsMina Blair-Robinson +44 (0)20 7304 5084 Jorgen Winroth +1 609 896 4148 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 05:52 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
